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Summary
Background: Evidence for the efficacy of TIPSS in ectopic variceal bleeding (EctVB)
is largely based on relatively small series.
Aim: To define the efficacy of TIPSS in EctVB.
Methods: Retrospective analysis of consecutive patients with chronic liver disease
who presented with EctVB and received TIPSS in three tertiary centres in 1992‐
2016.
Results: The study included 53 patients (70% male, median age 61 years, median
model for end‐stage liver disease (MELD) score 11). The ectopic varices were
located around the insertion of stomas (40%), duodenum (23%), rectum (17%) and
at other sites (20%). Three‐quarters of the patients had previously received unsuc-
cessful medical, endoscopic or surgical therapy. The median follow‐up was
14.0 months. Following TIPSS, bleeding recurred in 12 patients: 6 of 12 (50%) with
duodenal varices, 2 of 9 (22%) with rectal varices and one each with stomal
(1/21), intraperitoneal (1/3), hepaticojejunostomy (1/2) and ascending colon varices
(1/2). The risk factors for re‐bleeding were MELD score at TIPSS placement (HR:
1.081 per point; 95% confidence interval (CI): 1.012‐1.153; P = 0.034), varices
located at site other than an enterostomy (HR: 9.770; 95%CI: 1.241‐76.917;
P = 0.030) and previous local therapy (HR: 5.710; 95%CI: 1.211‐26.922; P = 0.028).
The estimated cumulative re‐bleeding rate was 23% at 1 year, 26% at 3 years and
32% at 5 years. Post‐TIPSS hepatic encephalopathy manifested or worsened in 16
of 53 patients (30%).
Conclusion: TIPSS provides long‐term control of bleeding in most cirrhotic patients
with EctVB. TIPSS is particularly effective in stomal EctVB, the most frequent cause
of EctVB, but might not be as effective in duodenal EctVB.
The Handling Editor for this article was Professor Peter Hayes, and it was accepted for
publication after full peer-review.
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1 | INTRODUCTION
Approximately 5% of variceal bleedings occur outside the cardio‐
oesophageal junction and are denoted as ectopic.1 Ectopic varices
are predominantly located in the small and large intestine and
around enterocutaneous stomas, but can also be present in the peri-
toneum, biliary tree and pelvic organs.2 Abdominal and pelvic surgery
is a well‐known risk factor because postoperative adhesions and the
creation of an enterostomy facilitate the formation of portosystemic
collaterals.1,2
The management of ectopic variceal bleeding (EctVB) is challeng-
ing and not based on the results of controlled trials. Local endo-
scopic treatment modalities (band ligation, injection sclerotherapy,
clips, argon plasma coagulation) and selective variceal embolisation
frequently fail to prevent rebleeding with reported recurrence rates
up to 80% within 6 months.3,4 Surgical treatment, such as local
sutures, devascularisation procedures or stoma revision with resiting,
will only occasionally provide long‐term control of bleeding in
selected patients. The creation of surgical portosystemic shunts is
associated with significant morbidity and mortality, particularly in
patients with decompensated cirrhosis, and is rarely performed
nowadays.5-7
TIPSS creation is used to treat patients suffering from EctVB.8
Although evidence suggests that TIPSS is usually effective to pre-
vent recurrent bleeding, research publications are restricted to
patient series including only 8‐28 patients.9-13 Also, variable results
have been published with respect to concomitant variceal embolisa-
tion, and the additional therapeutic value of embolisation combined
with TIPSS placement remains unclear.9,11-14
We therefore aimed, in a multicentre cohort of patients with
EctVB, to further determine the efficacy of TIPSS and to evaluate
outcomes in subgroups with different types of ectopic varices. We
also intended to explore the benefit of concomitant vascular emboli-
sation of collateral vessels feeding the ectopic varices.
2 | PATIENTS AND METHODS
2.1 | Study design and data collection
We included all consecutive patients with advanced chronic liver dis-
ease, who underwent TIPSS placement for EctVB using bare metal
stents or expanded polytetrafluoroethylene (e‐PTFE)–covered nitinol
stents (Viatorr, W.L. Gore & Associates Inc, Flagstaff, AZ, USA) in
three tertiary referral centres: Erasmus MC, Rotterdam, the Nether-
lands, between January 1992 and December 2016; Academic Medi-
cal Center (AMC), Amsterdam, the Netherlands, between January
1998 and December 2016; and UZ Leuven, Leuven, Belgium,
between January 2000 and December 2013. Demographic, biochem-
ical clinical and survival data were collected from patient hospital
records and entered into a database for statistical analysis. The study
protocol conforms to the ethical guidelines of the 1975 Declaration
of Helsinki as reflected in approval by the Medical Ethics Committee
Erasmus MC, Rotterdam, the Netherlands, on 18 April 2017 (MEC‐
2017‐217), stating that written informed consent was not necessary
considering the retrospective study design.
2.2 | Definitions
The diagnosis of advanced chronic liver disease was based on liver
histology, or a combination of clinical, biochemical and radiological
findings.15 The model for end‐stage liver disease (MELD) score was
calculated with the formula: 0.957 × log(creatinine in mg/dL) +
0.378 × log(bilirubin in mg/dL) + 1.120 × log(INR) + 0.643.16,17
Comorbidity with a cardiovascular condition, pulmonary condition or
renal condition was defined as a condition requiring long‐term medi-
cal treatment for which regular specialist follow‐up care was neces-
sary. Early TIPSS was defined as TIPSS insertion within 72 hours
after an EctVB episode.18 Bleeding was defined as a decrease in
haemoglobin (Hb) by 2 g/dL (1.24 mmol/L), or the requirement of
more than 2 units of packed red cells within 24 hours to stabilise
Hb concentration or signs of volume depletion (systolic blood pres-
sure below 100 mm Hg and/or heart rate above 100/min).13
Rebleeding was defined as a single episode of clinical significant
recurrent melena or hematemesis from portal hypertensive sources
after day 5 that resulted in any of the following: (a) hospital admis-
sion, (b) blood transfusion, (c) drop in Hb of 3 g/dL (1.86 mmol/L) or
(d) death within 6 weeks.19
The standard follow‐up protocol for stent function differed per
centre: in the Erasmus MC, a functional assessment of bare TIPSS
stents with Doppler ultrasound (US) was performed 2, 7 and 30 days
after placement, at 3‐month intervals during the first year of follow‐
up, and every 6 months thereafter. Following TIPSS with covered
stents, standard follow‐up imaging was not performed. In the AMC,
all stents were assessed at 3‐7 days, 3 months, 6 months and
12 months after placement, and every year thereafter. In UZ Leuven,
stent function was assessed every 6 months. In all centres, patients
received an angiography with venous portal pressure measurements
when shunt dysfunction was suspected based on findings during
Doppler US or clinical symptoms. Shunt dysfunction was defined as
shunt stenosis greater than 50% of the shunt and/or hepatic venous
portal gradient higher than 12 mm Hg.20
2.3 | Statistical analysis
Continuous variables were reported as mean with standard deviation
(SD), after visual confirmation of approximate normality, and com-
pared using a T test. A median and range from the first to the third
quartile (IQR, interquartile range) was computed for continuous vari-
ables with a non‐normal distribution and compared using a Mann‐
Whitney test. Categorical variables were reported as count with pro-
portion and compared using the chi‐squared test.
The actuarial probabilities of being free of shunt dysfunction
(shunt dysfunction as event, censoring at death or liver transplanta-
tion), being free of rebleeding (rebleeding as event, censoring at
death or liver transplantation) and transplant‐free survival (death as
event, censoring at liver transplantation) after TIPSS creation were
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estimated using the Kaplan‐Meier method and compared using log‐
rank tests.
A univariable Cox regression analysis was carried out to identify
risk factors for rebleeding at TIPSS placement using candidate pre-
dictor variables, hereinafter mentioned, as described in the literature
and based on the clinical and research experiences of co‐investiga-
tors: MELD score, location of EctVB, local treatment of the EctVB,
urgency placement of TIPSS, type of stent used during TIPSS, portal
pressure gradient after TIPSS placement above 12 mm Hg and con-
comitant embolisation.2,11-13,18,21,22 The univariable Cox regression
models were adjusted with a propensity score to take into account
differences in MELD score at TIPSS placement for each individual
covariate.
Furthermore, the effect of concomitant embolisation during the
TIPSS procedure compared to TIPSS alone on rebleeding and mortal-
ity was analysed. For this analysis as well, a propensity score was
calculated using a logistic regression model, estimating the probabil-
ity to receive concomitant embolisation given the following observed
baseline characteristics: MELD score, location of EctVB, type of
stent used during TIPSS and urgency placement of TIPSS as predic-
tor variables.
A two‐sided P < 0.05 was considered significant for descriptive
statistics, and a P‐value <0.10 was considered significant for univari-
able regression models. All statistical analyses were performed using
IBM SPSS Statistics for Windows, version 24.0 (IBM Corp., Armonk,
NY, USA).
3 | RESULTS
3.1 | Patient characteristics and TIPSS procedures
In the three centres, 53 patients received TIPSS for EctVB during
the study period, representing 5.4% of the total population (n = 979)
undergoing a TIPSS procedure (Figure 1). The study population con-
sisted predominantly of males with a median age of 61 years (IQR
51‐66) and a median MELD score of 11 (IQR 9‐17; Table 1). The
ectopic varices were most often located near the mucocutaneous
junction of stomas (40%), followed by the duodenum (23%), rectum
(17%) and other sites (20%). TIPSS placement was the initial treat-
ment for EctVB in 23% of the patients. About 77% of the patients
had been unsuccessfully treated for EctVB with one or multiple
modalities; 24 patients (45%) had undergone previous endoscopic
treatment (band ligation, injection therapy, coagulation), 22 (42%)
had received vasoactive medication (nonselective beta‐blockers,
somatostatin, terlipressin), 9 (17%) had undergone abdominal surgery
(stoma revision or relocation, bowel resection) and 1 patient (2%)
had received endovascular treatment (embolisation).
TIPSS were created with a bare metal stent in 8 patients and
with an e‐PTFE–covered stent in 45 patients (Table 2). Hemody-
namic measurements showed that the median pre‐TIPSS portosys-
temic gradient (PSG) decreased from 14 mm Hg (IQR 10‐20) to
6 mm Hg (IQR 4‐7) after TIPSS placement. The post‐TIPSS PSG
remained above 12 mm Hg in four patients. Eighteen (34%) patients
received early TIPSS and initial hemostasis was achieved in all cases.
3.2 | Clinical outcome
The median follow‐up time was 14.0 months (IQR 3.8‐45.9). Follow-
ing TIPSS, EctVB from the same site occurred in 12 of 53 (23%)
patients (Figure 2). Bleeding recurred in 1 of 21 (5%) cases with sto-
mal varices, 6 of 12 (50%) cases with duodenal varices, in 2 of 9
(22%) with rectal varices, in 1 of 3 cases with intraperitoneal varices,
in 1 of 2 cases with varices in the ascending colon and in 1 of 2
cases with varices located at the hepaticojejunostomy. The four
patients with jejunal, caecal, sigmoid or umbilical vein ectopic varices
remained free of rebleeding.
Most rebleeds were diagnosed shortly after TIPSS creation, in
eight patients (four with duodenal varices, one with varices at the
hepaticojejunostomy, one with intraperitoneal varices, one with rec-
tal varices and one with ascending colon varices) in the first month
after the TIPSS procedure (15%), in two patients (one with duodenal
varices and one with rectal varices) after 1‐6 months (4%) and in
two patients (one with duodenal varices and one with urostomal
varices) after 6 months (4%). In nine of these 12 patients, rebleeding
was associated with shunt dysfunction. After TIPSS placement, the
estimated cumulative ectopic variceal rebleeding rate was 23% at
1 year, 26% at 3 years and 32% at 5 years (Figure 3). Rebleeding
from other sources occurred in four patients: three from gastro‐
oesophageal varices and one from haemorrhagic gastropathy. The
univariable Cox regression to identify risk factors for rebleeding
found three predicting variables: high MELD score (HR: 1.081 per
point; 95% confidence interval, CI: 1.012‐1.153; P = 0.020), EctVB
located at another site than an enterostomy (HR: 9.770; 95% CI:
1.241‐76.917; P = 0.030) and local treatment preceding TIPSS (HR:
5.710; 95% CI: 1.211‐26.922; P = 0.028) (Table 3).
The rebleeding risk in the two main subcategories of EctVB—
stomal and duodenal varices—differed markedly. A comparison of
these groups with respect to aetiology of liver disease, MELD score,
type of stent, concomitant embolisation, post‐TIPSS PSG >12 mm
Hg and established stent dysfunction did not reveal significant differ-
ences. However, age was significantly lower in patients with duode-
nal EctVB (54 vs 65 years, P = 0.016), and 11 of 12 duodenal EctVB
had been treated endoscopically before TIPSS, while local endo-
scopic or other procedures were performed in only 2 of 21 cases
with stomal EctVB (P < 0.001) (Figure S1).
TIPSS dysfunction was diagnosed in 6 of 8 patients with bare
metal stents (75%) compared to 10 of 45 with e‐PTFE–covered
stents (22%) (P = 0.011). In six patients, shunt dysfunction was diag-
nosed at an elective follow‐up visit and in nine patients after a
rebleed. Most shunt dysfunctions were diagnosed in the first
6 months after TIPSS creation, in seven patients in the first month
(13%), in 6 after 1‐6 months (11%) and in three after 6 months (6%).
The estimated cumulative TIPSS dysfunction rate significantly dif-
fered (P = 0.003) for bare metal stents (1 year: 76%; 3 years: 100%)
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compared to e‐PTFE–covered stents (1 year: 23%; 3 years: 24%;
5 years: 31%) (Figure 4).
A total of 31 shunt revisions were performed in the first 2 years
after TIPSS creation in 13 patients. An additional stent was placed in
eight patients; in four patients, angioplasty was performed (followed
in two cases by additional stent placements); and in one patient,
local thrombolysis was accomplished. Three patients with shunt dys-
function and rebleeding died.
Post‐TIPSS hepatic encephalopathy (HE) manifested or worsened
in 16 of 53 patients (30%). HE could be managed medically in 12
patients; however, in four patients radiological re‐intervention was
performed reducing the TIPSS diameter and improving or resolving
in all cases the symptoms of HE. In no cases, a complete shunt
occlusion was performed.
In this cohort, 41 patients died, five underwent liver transplanta-
tion, six were alive at the end of follow‐up, and one was lost to fol-
low‐up. The causes of death were liver disease‐related in 12 patients
(29.3%) including three patients dying of EctVB, not liver disease‐
related in 12 patients (29.3%), and unknown in 17 patients (41.4%)
(Figure 2). The estimated 30‐day, 1‐year and 5‐year mortality rates
were 11%, 41% and 75%, respectively (Figure S2).
3.3 | Concomitant embolisation during TIPSS
Concomitant embolisation during the TIPSS procedure was performed
in 13 patients: four patients had varices located near enterocutaneous
stomas, four had duodenal varices, two had rectal varices, two had
intraperitoneal varices and one had varices in the ascending colon.
Concomitant embolisation was performed in 4 of 9 patients with an
acute bleeding and in 9 of 44 patients as a secondary prophylactic
measure. There were no statistically significant differences between
patients receiving embolisation and TIPSS alone with respect to age,
gender, MELD score, location of varices, presentation with acute
bleeding or treatment centre. After propensity score adjustment, the
hazard ratio for rebleeding of concomitant embolisation compared to
TIPSS alone was 0.701 (95% CI: 0.145‐3.390; P = 0.659) and the haz-
ard ratio for mortality was 0.776 (95% CI: 0.281‐2.148; P = 0.626).
4 | DISCUSSION
This multicentre cohort study evaluated the efficacy of TIPSS with
predominantly e‐PTFE–covered stents in subgroups of patients with
Ectopic variceal 
bleeding
n = 26
Ectopic variceal 
bleeding
n = 15
Patients with TIPSS
in Erasmus MC, 
Rotterdam, the 
Netherlands
January 1992-
December 2016
n = 438
Ectopic variceal 
bleeding
n = 12
Patients with bleeding ectopic varices and TIPSS placement
n = 53
Bare metal stent
n = 8
Patients with TIPSS
in AMC, Amsterdam, 
the Netherlands
January 1998-
December 2016
n = 187
Patients with TIPSS
in UZ Leuven, 
Belgium
January 2000-
December 2013
n = 354
e-PTFE–covered stent
n = 45
F IGURE 1 Flow diagram of inclusion.
e‐PTFE: expanded polytetrafluoroethylene
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TABLE 1 Clinical characteristics of the study population
Patients with ectopic
variceal bleeding
(n = 53)
Male gender (%) 37 (69.8)
Age in years, median (IQR) 61 (51‐66)
Aetiology of portal hypertension (%)
Alcoholic cirrhosis 25 (47.2)
PSC/PBC/autoimmune hepatitis 11 (20.8)
Cryptogenic cirrhosis 7 (13.2)
Viral hepatitis 2 (3.8)
Other 8 (15.0)
Child‐Pugh classa (%)
A 34 (65.4)
B 15 (28.8)
C 3 (5.8)
MELD score,a median (IQR) 11 (9‐18)
Portal vein thrombosis (%) 5 (9.4)
Comorbidityb (%)
Previous medical history
of malignancyc
11 (20.8)
Colorectal cancer 5
Urothelial carcinoma 3
Pancreatic cancer 2
Hepatocellular cancer 1
Lung cancer 1
Hodgkin's disease 1
Cardiovascular condition 9 (17.0)
Inflammatory bowel disease 8 (15.1)
Diabetes 6 (11.3)
Pulmonary condition 4 (7.6)
Renal condition 4 (7.6)
Medical history of
gastroesophageal
variceal bleeding (%)
8 (15.1)
Number of previous episodes of gastroesophageal variceal bleeding (%)
1‐3 6 (11.3)
4‐6 1 (1.9)
7 or more 1 (1.9)
History of abdominal
surgery (%)
36 (67.9)
(Continues)
TABLE 1 (Continued)
Patients with ectopic
variceal bleeding
(n = 53)
Location of bleeding ectopic varices (%)
Enterostomald 21 (39.7)
Colostomy 11
Ileostomy 8
Urostomy 3
Duodenum 12 (22.6)
Rectum 9 (17.0)
Intraperitoneal 3 (5.7)
Hepaticojejunostomy 2 (3.8)
Ascending colon 2 (3.8)
Jejunum 1 (1.9)
Caecum 1 (1.9)
Sigmoid 1 (1.9)
Umbilical vein 1 (1.9)
Number of previous episodes of ectopic variceal bleeding (%)
1‐3 26 (49.1)
4‐6 7 (13.2)
7 or more 20 (37.7)
Previous treatment of ectopic variceal bleeding (%)
None 12 (22.6)
Medicationb 22 (41.5)
Non‐selective β‐blocker 14
Somatostatin 12
Terlipressin 1
Endoscopicb 24 (45.3)
Band ligation 9
Injection therapy 17
Coagulation 2
Endovascular embolisationb 1 (1.9)
Surgeryb 9 (16.9)
IQR: interquartile range; MELD: model for end‐stage liver disease.
aData regarding liver disease severity missing in 1 case.
bPatients could have multiple concomitant comorbidities or received mul-
tiple treatment modalities, either concomitant or successive.
cTwo patients had a history with two malignancies.
dOne patient presented with concomitant colostomy and urostomy
bleeding.
bleeding from ectopic varices. The present study confirms that TIPSS
was an effective treatment by completely preventing rebleeding in
the large majority (77%) of cases. TIPSS was particularly effective in
patients with less severe liver disease and with varices located at
enterostomas. In contrast, the rebleeding risk in patients with duode-
nal varices was unexpectedly high.
The observed cumulative 23% rebleeding rate at 1 year is com-
parable with previously reported rates varying from 23% to 39%,11-
13 while the 26% rate at 2 years was considerably lower than
previously reported.12 It seems likely that the superior long‐term
bleeding control is attributable to the use of e‐PTFE–covered stents
in the large majority of cases. The actuarial risk of remaining free
from rebleeding in the present series in comparison with the risk
observed in TIPSS‐treated gastro‐oesophageal bleeding reported in
two recently published studies originating from the participating cen-
tres was 77% versus 94‐100% at 1 year, 74% versus 92‐94% at
3 years and 68% versus 90‐92% at 5 years, respectively.22,23 Thus,
the overall rebleeding risk in TIPSS‐treated EctVB appears to be
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higher than that in gastro‐oesophageal bleeding. Our data indicate
that this seems attributable to the relevant high rebleeding risk in
TIPSS‐treated duodenal EctVB.
In our cohort, shunt dysfunction was diagnosed in three‐quarter
of the patients with rebleeding and occurred three times more often
in bare metal stents compared to e‐PTFE–covered stents. In total,
TABLE 2 TIPSS procedural data
All patients
(n = 53)
Patients with
bare metal
stents (n = 8)
Patients with
e‐PFTE–covered
stents (n = 45)
Pre‐TIPSS placement PSG (mm Hg), median (IQR) 14 (10‐20) 22 (12‐26) 14 (9‐19)
Post‐TIPSS placement PSG (mm Hg), median (IQR) 6 (4‐7) 12 (7‐16) 5 (4‐7)
Decrease in PSG (mm Hg), median (IQR) 8 (6‐13) 8 (6‐12) 8 (6‐13)
Concomitant embolisation (%) 13 (24.5) 1 (12.5) 12 (26.7)
Early TIPSS placement (%) 18 (34) 4 (50) 14 (31)
Diameter stent (mm), median (IQR) 9 (8‐10) 9 (8‐10) 9 (8‐10)
e‐PTFE: expanded polytetrafluoroethylene; IQR: interquartile range; PSG: portosystemic gradient.
332 3 7
3
7
4
7
2
6
2
6
103526
31
6
5
1 7
Stent revision
n = 6
Deceased, 
cause of death:
- liver disease-related 
(n = 9)
- non liver disease-
related (n = 12)
-unknown (n = 17)
n = 38
(72%)
Alive/lost to 
follow-up
n = 6/n = 1 
(13%)
TIPSS treatment for ectopic
varices with 
bare metal stents
n = 8
(15%)
TIPSS treatment for ectopic
varices with 
e-PTFE–covered stents
n = 45
(85%)
Deceased, related to
ectopic variceal
rebleeding.
n = 3
(6%)
Stent stenosis
- diagnosed at 
follow-up visit (n = 4)
- diagnosed after 
rebleeding (n = 2)
n = 6
Stent patent
n = 8
Rebleeding
n = 2
Free of
rebleeding
n = 6
Stent stenosis
- diagnosed at 
follow-up visit (n = 3)
- diagnosed after 
rebleeding (n = 7)
n = 10
Stent patent
n = 42
Stent revision
n = 7
Rebleeding
n = 10
Free of
rebleeding
n = 35
Liver 
transplantation
n = 5
(9%)
F IGURE 2 Rebleeding, stent patency
and clinical outcome in patients with bare
metal stents and e‐PTFE–covered stents. e‐
PTFE: expanded polytetrafluoroethylene
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TIPSS dysfunction occurred in 23% at 1‐year follow‐up compared to
approximately 20% in the study from Kochar et al and 49% in the
study from Vidal et al.12,13 Although these rates vary notably, the
trend that e‐PTFE–covered stents have improved shunt patency is in
line with widely reported experience.24,25
In our series, the efficacy of TIPSS in patients with duodenal
EctVB, who had a disappointing 50% rebleeding risk, was relatively
poor. A potential explanatory factor may be that local, but ultimately
unsuccessful endoscopic therapies frequently preceded TIPSS. In our
experience, endoscopic treatment, in particular repeated tissue glue
injections, may lead to significant duodenal ulcerations that can be
the cause of repeated bleeding in their own right. In such cases, it
may be very difficult to distinguish portal hypertensive‐related bleed-
ing from other causes, and management may be troublesome.
Another possibility is that local tumorous vascular ingrowth or
thrombosis could cause (re)bleeding unrelated to portal hypertension.
However, in our two cases with duodenal variceal bleeding and a
previous diagnosis of pancreatic cancer, there was no evidence for
residual or recurrent tumour. Also with respect to other malignan-
cies, there was no indication that these were of aetiological impor-
tance. Further studies in this type of EctVB are required to further
address the timing of TIPSS and whether alternative therapeutic
approaches, in particular balloon‐occluded retrograde‐transvenous‐
obliteration may be a preferable strategy.26
The efficacy of TIPSS has to be balanced against the risk of
serious side effects, in particular HE. Post‐TIPSS HE manifested or
worsened in 30% of our patients, which was comparable with
other reported experience.18,23,27,28 The majority of post‐TIPSS HE
could be managed medically, but in some cases, a stent diameter
reduction was necessary. A recent report suggests that there might
be an optimum of 8 mm TIPSS diameter to effectively decompress
the portal system in relation to the encephalopathy risk.29 With
the knowledge that the diameter of TIPSS can passively increase
after placement, improved results regarding post‐TIPSS HE may be
expected in the future for diameter controlled expansion
stents.30,31
A recent meta‐analysis found a nonsignificant trend towards a
beneficial effect of variceal embolisation in addition to TIPSS.14 Our
data are in line with these results as embolisation did not signifi-
cantly improve the probability of remaining free of rebleeding or sur-
vival. However, considering the potential selection bias occurring
when embolisation of the culprit varix is not feasible and the limited
number of patients treated, we were unable to reliably assess the
value of embolisation as an adjunctive measure.
To the best of our knowledge, we report the largest multicen-
tre cohort of patients with TIPSS for EctVB with predominantly e‐
PTFE–covered stents and our data reflect real‐life practice in three
university hospitals. Despite the retrospective study design, only
one patient was lost to follow‐up. This is the first study allowing a
preliminary assessment of the efficacy of TIPSS in subgroups of
EctVB, although the results should be interpreted cautiously con-
sidering the size of the patient population. Ideally, prospective tri-
als could provide more clarity about the role of TIPSS in
subgroups of EctVB as well as on the role of concomitant emboli-
sation. However, such studies may never be performed considering
the low prevalence of the disease, the heterogeneity in varices
location and the technical inability to embolise all culprit collateral
vessels.
In conclusion, our study demonstrates that TIPSS effectively pre-
vents rebleeding in the majority of patients presenting with EctVB.
TIPSS is particularly effective in bleeding from enterostomas, the
most frequent type of EctVB. However, the results in duodenal
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F IGURE 3 Actuarial probability (red line) with 95% confidence
interval (black dashed lines) of remaining free of rebleeding following
TIPSS
TABLE 3 Univariable analysis of ectopic variceal rebleeding
HR 95% CI P‐value
MELD score (per point) 1.081 1.012‐1.153 0.020
Location of ectopic varicesa
Enterostomal 1 0.030
Other site 9.770 1.241‐76.917
Previous local therapya 5.710 1.211‐26.922 0.028
Early placement of TIPSSa
≤72 h after EctVB episode
(reference)
1 0.653
>72 h after EctVB episode 0.737 0.195‐2.787
Type of TIPSSa
Bare (reference) 1 0.887
e‐PTFE‐covered 0.9894 0.193‐4.148
Post‐TIPSS PSGa
≤12 mm Hg (reference) 1 0.884
>12 mm Hg 1.171 0.141‐9.735
Concomitant embolisationa 1.133 0.304‐4.221 0.852
CI: confidence interval; e‐PTFE: expanded polytetrafluoroethylene;
EctVB: ectopic variceal bleeding; HR: hazard ratio; MELD: model for end‐
stage liver disease; PSG: portosystemic gradient.
aHazard ratio adjusted with propensity score for MELD score at TIPSS
placement.
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EctVB, with a 50 per cent rebleeding rate, were disappointing and
highlight the need for alternative therapeutic approaches.
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